FDA Expands Gene Therapy for Younger Patients - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

  • By

  • Kathryn Wighton

  • July 2, 2026

  • 3 min

Share

Original Source(s)

FDA Expands Gene Therapy for Younger Patients

  • by Kathryn Wighton

  • July 2, 2026

Related Content

Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension

Case Report: Congenital pulmonary airway malformation associated with a germline DICER1 splicing variant

Editorial: Management of testicular microlithiasis in children